The main purpose of this legislation, known as the Shane DiGiovanna Act, is to establish a program that tests whether mandatory coverage for wound care treatment for epidermolysis bullosa (EB) should be included under Medicaid. This is aimed at improving access to necessary medical supplies and treatments for individuals suffering from this rare skin condition. Key provisions of the Act require the Secretary of Health and Human Services to initiate a two-year demonstration program within a year of the law's enactment.